Chronic Obstructive Pulmonary Disease Virtual Reality Therapy Market Report 2025

The chronic obstructive pulmonary disease virtual reality therapy market size has grown rapidly in recent years. It will grow from $1.15 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 19.7%. The growth during the historic period is linked to the increasing prevalence of chronic obstructive pulmonary disease (COPD), growing demand for non-pharmacological interventions, rising adoption of digital health solutions, need for cost-effective rehabilitation options, and greater awareness of the benefits of remote therapy.

The chronic obstructive pulmonary disease virtual reality therapy market size is expected to see rapid growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 19.3%. The growth projected for the forecast period is driven by increasing adoption of home-based rehabilitation, expanding healthcare digitization and telemedicine, rising healthcare expenditure in emerging markets, supportive reimbursement policies for digital therapeutics, and greater focus on reducing hospital readmissions. Primary trends during the forecast period include integration of virtual reality (VR) with artificial intelligence for personalized therapy, use of cloud-based platforms for remote pulmonary rehabilitation, incorporation of haptic feedback for immersive breathing exercises, adoption of digital twins for respiratory health simulation, and integration with wearable sensors for real-time monitoring.

Growing awareness and acceptance of virtual reality therapy are expected to drive growth in the chronic obstructive pulmonary disease virtual reality therapy market. Virtual reality therapy uses immersive technology to create interactive environments for treatment and rehabilitation. The increasing recognition of this therapy stems from its ability to reduce pain and anxiety, providing patients with a non-invasive, drug-free option that enhances treatment experiences and results. Awareness boosts adoption by educating patients and providers, encouraging the use of digital rehabilitation solutions. It also improves engagement by familiarizing users with immersive therapy, resulting in better adherence and health outcomes. For example, in July 2024, the U.S. Department of Veterans Affairs reported that approximately 3,500 virtual reality headsets were deployed across over 170 VA medical centers and outpatient clinics, tripling the number available for therapeutic purposes. This rise in awareness and acceptance is fueling the growth of the COPD virtual reality therapy market.

The growing focus on personalized medicine is also expected to support expansion of the chronic obstructive pulmonary disease virtual reality therapy market. Personalized medicine customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environment. Advances in genomics have made it possible to identify genetic variations precisely and provide tailored treatments. Personalized medicine enhances COPD virtual reality therapy by adapting immersive rehabilitation programs to meet each patient’s specific needs, increasing treatment effectiveness and focus. It improves outcomes by addressing unique symptoms, abilities, and preferences, which strengthens patient engagement and adherence. For instance, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a notable rise from 12 approvals in 2022. This growing emphasis on personalized medicine is propelling the COPD virtual reality therapy market forward.

In March 2025, Wellinks Inc., a digital healthcare company based in the United States, formed a partnership with CareAbout Health to broaden virtual-first COPD management programs within value-based care networks. This collaboration seeks to improve patient outcomes, lower hospitalization rates, and increase access to comprehensive home pulmonary care. CareAbout Health is a healthcare management company in the U.S. that supports virtual COPD care initiatives.

Major players in the chronic obstructive pulmonary disease virtual reality therapy market are Inova Health System, Rush University Medical Center, Penumbra Inc., Burke Rehabilitation Hospital, MindMaze SA, XRHealth Inc., Jolly Good Inc., AppliedVR Inc., Carda Health Inc., Lincare Inc., Virtually Better Inc., Wellinks Inc., Breathe Better Rehab, Kivo Health Inc., and VRelax B.V.

North America was the largest region in the chronic obstructive pulmonary disease virtual reality therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic obstructive pulmonary disease virtual reality therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chronic obstructive pulmonary disease virtual reality therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Chronic obstructive pulmonary disease (COPD) virtual reality therapy is a non-pharmacological treatment approach that uses immersive virtual reality environments to support respiratory rehabilitation, enhance lung function, and increase patient engagement. It combines interactive exercises, breathing techniques, and real-time feedback to help patients manage symptoms and improve overall quality of life. This therapy is increasingly integrated into digital health solutions for home-based and clinical pulmonary care.

The primary components of COPD virtual reality therapy include hardware, software, and services. Hardware refers to virtual reality headsets, sensors, wearables, and related devices used to deliver immersive, interactive therapies for pulmonary rehabilitation, breathing exercises, and symptom management in COPD patients. Therapy types include immersive and non-immersive virtual reality approaches. Applications cover pulmonary rehabilitation, patient education, pain management, anxiety and stress reduction, and other areas. Key end users include hospitals, clinics, home care settings, and other healthcare providers.

The chronic obstructive pulmonary disease virtual reality therapy market research report is one of a series of new reports that provides chronic obstructive pulmonary disease virtual reality therapy market statistics, including the chronic obstructive pulmonary disease virtual reality therapy industry global market size, regional shares, competitors with the chronic obstructive pulmonary disease virtual reality therapy market share, detailed chronic obstructive pulmonary disease virtual reality therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic obstructive pulmonary disease virtual reality therapy industry. This chronic obstructive pulmonary disease virtual reality therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic obstructive pulmonary disease virtual reality therapy market consists of revenues earned by entities by providing services such as virtual pulmonary rehabilitation programs, guided breathing and relaxation sessions, remote respiratory therapy, patient education and training modules, tele-rehabilitation support, gamified exercise sessions, and social interaction platforms. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic obstructive pulmonary disease virtual reality therapy market also includes sales of virtual reality (VR) headsets, motion controllers, haptic feedback devices, specialized respiratory training software, cloud-based therapy platforms, and virtual reality (VR)-enabled monitoring systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.